Summary by Moomoo AI
Cornerstone Pharmaceuticals announced a strategic partnership with Ewopharma to commercialize its developed anti-PD-L1 monoclonal antibody — Sugarlicone Antibody in Middle East Europe and Switzerland. The partnership covers 18 Middle Eastern European countries and Switzerland, and Keystone Pharmaceuticals will receive up to $5130 million in initial and follow-up milestone payments and generate international revenue through product sales. Sugarlicone has been approved for five indications in China and is expected to receive approval from the European Medicines Agency (EMA). Keystone Pharmaceuticals will be responsible for product supply and brand support, while Ewopharma will be responsible for pricing, reimbursement, marketing and distribution. Both leaders expressed positive anticipation for the collaboration, which they believe will advance the clinical and commercial value of Sugarlicone in the European market and bring new hope to patients. IN ADDITION, PEBBLE PHARMACEUTICALS IS COMMUNICATING WITH MULTIPLE REGULATORY AGENCIES AROUND THE WORLD TO ACTIVELY PURSUE GLOBAL DEVELOPMENT AND COMMERCIALIZATION COOPERATION.